Variant position: 713 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 770 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human EDVGSNKGAIIGLMVGGVVI ATVI-VITLVMLKKKQYTSIH-H
Chimpanzee EDVGSNKGAIIGLMVGGVVI ATVI-VITLVMLKKKQYTSIH
Mouse EDVGSNKGAIIGLMVGGVVI ATVI-VITLVMLKKKQYTSIH
Rat EDVGSNKGAIIGLMVGGVVI ATVI-VITLVMLKKKQYTSIH
Pig EDVGSNKGAIIGLMVGGVVI ATVI-VITLVMLKKKQYTSIH
Caenorhabditis elegans EVERSASSVFQPYVLASAMF ITAICIIAFAITNARRRRAM-
Drosophila HAAKEGRNVYFTLSFAGIAL MAAV-FVGVAVAKWRTSRSPH
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
18 – 770 Amyloid-beta A4 protein
672 – 770 C99
672 – 713 Amyloid-beta protein 42
688 – 770 C83
688 – 713 P3(42)
691 – 770 C80
712 – 770 Gamma-secretase C-terminal fragment 59
702 – 722 Helical
704 – 704 Implicated in free radical propagation
706 – 706 Susceptible to oxidation
713 – 714 Cleavage; by gamma-secretase; site 2
729 – 729 Phosphothreonine
730 – 730 Phosphoserine; by APP-kinase I
306 – 770 Missing. In isoform APP305.
704 – 704 G -> V. Reduced protein oxidation. No hippocampal neuron toxicity.
706 – 706 M -> L. Reduced lipid peroxidation inhibition.
706 – 706 M -> V. No free radical production. No hippocampal neuron toxicity.
717 – 717 V -> CS. Unchanged amyloid-beta protein 42/total amyloid-beta ratio.
717 – 717 V -> FGI. Increased amyloid-beta protein 42/40 ratio.
717 – 717 V -> K. Decreased amyloid-beta protein 42/total amyloid-beta ratio.
717 – 717 V -> M. Increased amyloid-beta protein 42/40 ratio. No change in apoptosis after caspase cleavage.
728 – 728 Y -> A. No effect on APBA1 nor APBB1 binding. Greatly reduces the binding to APPBP2. APP internalization unchanged. No change in amyloid-beta protein 42 secretion.
More missense in amyloid gene.
Carter D.A.; Desmarais E.; Bellis M.; Campion D.; Clerget-Darpoux F.; Brice A.; Agid Y.; Jaillard-Serradt A.; Mallet J.;
Nat. Genet. 2:255-256(1992)
Cited for: VARIANT AD1 THR-713;
A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene.
Rossi G.; Giaccone G.; Maletta R.; Morbin M.; Capobianco R.; Mangieri M.; Giovagnoli A.R.; Bizzi A.; Tomaino C.; Perri M.; Di Natale M.; Tagliavini F.; Bugiani O.; Bruni A.C.;
Cited for: VARIANT AD1 THR-713;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.